Combination pharmacotherapy in the management of patients with hard-to-treat erectile dysfunction

Journal of Sexual Medicine

Volumn 3, Issue 1, 2006, Pages 185-187

  Chew, K K ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CALCIUM ION; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIN; GUANYLATE CYCLASE; NEUROPEPTIDE Y; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROSTANOID; VASOACTIVE INTESTINAL POLYPEPTIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME ACTIVATOR; PHOSPHODIESTERASE INHIBITOR; VASODILATOR AGENT;

CALCIUM CELL LEVEL; CALCIUM DEPLETION; DRUG CONTRAINDICATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; LETTER; MALE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG COMBINATION; IMPOTENCE;

ADRENERGIC ALPHA-ANTAGONISTS; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; ENZYME ACTIVATORS; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 33645736614     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2005.00101.x     Document Type: Article

References (21)

1. Eardley I, Sethia K. Anatomy and physiology of erection in erectile dysfunction: Current investigation and management. London: Mosby-Wolfe Medical Communications; 1998.
2. Heaton JPW, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: An evolutionary imperative. IJIR 1997;9:115-21.
3. Sazova O, Kadioglu A, Güran L, Kayaarasi Z, Bross S, Manning M, Jünemann KP. Intracavernous administration of SIN-1 + VIP in an in vivo rabbit model for erectile function. IJIR 2002;14:44-9.
4. Son HC, Park JY, Kang JY, Kim SW, Paick JS. The synergistic effect of apomorphine on sildenafil induced penile erection in the awake rabbit. IJIR 2002;14:S5.
5. Lammers PI, Rubio-Auriolles E, Castell R, Casteneda J, Ponce de Leon R, Hurley D, Lipezker M, Loehr LA, Lowrey F. Combination therapy for erectile dysfunction: A randomised, double-blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. IJIR 2002;14:54-9.
6. Claes H, Sorgeloose T, Van Poppel H, Baert L, Gasthuisberg UZ. The use of sildenafil and apomorphine in clinical practice. IJIR 2002;14:S86.
7. El-Taweel A, Esawy O, Waly A. Efficacy and tolerability of combination of sildenafil citrate and apomorphine in sublingual tablet form by EIPICO-Egypt. 4th Asian & Oceanic Congress of Andrology Abstract Book 2004; p. 31.
8. Porst H. The potential of sildenafil (ViagraTM) for salvage therapy in severe male impotence. IJIR 1998;10:S67.
9. Dmitriev DG, Gamidov SI, Ovchinnikov RI, Mazo EB, Tirsi KA. Advantages of combining of sildenafil and alprostadil taken by nonresponders to monotherapy of erectile dysfunction. IJIR 2002;14:S86.
10. Gutierrez P, Hernandez P, Jimenez A, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. IJIR 2002;14:S37.
11. McMahom CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999;162:1992-7.
12. Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. IJIR 2002;14:S38.
13. Mydlo JH, Volpe MA, MacChia RJ. Results from different patient populations using combined therapy with alprostadil and sildenafil: Predictors of satisfaction. BJU Int 2000;86:469-73.
14. Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989;64:191-4.
15. Marques HJA, Chveizer H. Positive results of sodium nitroprusside + phentolamine as a new ICI drug combination for erectile dysfunction. IJIR 2002;14:S90.
16. Yassin AA, Diede HE. Tadalafil and α1-adrenoreceptor blockade: Combination ED therapy in BPH population. 4th Asian & Oceanic Congress of Andrology Abstract Book 2004; p. 44.
17. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998;52:739-43.
18. De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. IJIR 2002;14:50-3.
19. Peterson CA, Bennett AH, Hellstrom WJ, Kaiser FE, Morley JE, Nemo KJ, Padma-Nathan H, Place VA, Predergast JJ, Tam PY, Tanagho EA, Todd LK, Varady JC, Gesundheit N. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol 1998;159:1523-7.
20. Lebret T, Herve JM, Gorny P, Worcel M, Botto H. Efficacy and safety of a novel combination of 1-arginine glutamate and yohimbine hydrochloride: A new oral therapy for erectile dysfunction. Eur Urol 2002;41:608-13.
21. McMahon CG. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy. IJIR 2003;15:383-4.